Highlights Zai Lab Limited

Equities

ZLAB

US98887Q1040

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
16.12 ^USD	+1.32%		+6.61%	-41.02%

Apr. 17	Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading	MT
Apr. 11	Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bristol-Myers Squibb Therapy for Pretreated Non-Small Cell Lung Cancer Meets Primary Endpoint	Apr. 01	MT
Zai Lab Reports Lesser Loss in 2023	Mar. 27	MT
Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	Mar. 27	CI
Asian Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading	Mar. 20	MT
Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate for Treatment of Solid Tumors	Mar. 13	CI
Zai Lab's Loss Narrows in 2023	Feb. 28	MT
Earnings Flash (ZLAB) ZAI LAB LIMITED Reports 2023 Revenue $266.7M	Feb. 27	MT
Zai Lab Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Zai Lab Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Zai Lab Announces the New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC	Jan. 10	CI
Zai Lab Shares Climb as Vyvgart, Nuzyra, Zejula Added to 2023 China Reimbursement Drug List	Dec. 13	MT
Zai Lab Says China Added Vyvgart, Nuzyra, Zejula to 2023 Reimbursement Drug List	Dec. 13	MT
Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List	Dec. 12	CI
Zai Lab's Q3 Loss Narrows, Revenue Increases	Nov. 08	MT
Zai Lab's Q3 Loss Narrows as Revenue Rises	Nov. 07	MT
Earnings Flash (ZLAB) ZAI LAB LIMITED Posts Q3 Revenue $69.2M, vs. Street Est of $66.4M	Nov. 07	MT
Zai Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Zai Lab's Shares Rise After Repotrectinib Gets Chinese Breakthrough Therapy Designation to Treat Certain Solid Tumors	23-08-30	MT
Zai Lab's Repotrectinib Gets Chinese Breakthrough Therapy Designation to Treat Certain Solid Tumors	23-08-30	MT
Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China	23-08-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Zai Lab Limited

Equities

ZLAB

US98887Q1040

Highlights

Filters